MayerFishmanMD

Oncology • Riverview, FL

Associate Professor of Medicine, University S Fla College of Medicine

Join to view full profile

Dr. Fishman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Fishman's full profile

Already have an account?

Office
3140 South Falkenburg Road
Suite 104
Riverview, FL 33578
Phone+1 813-660-7150

Fax+1 813-660-6627
Is this information wrong?

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 1997 - 2000
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1993 - 1996
University of Maryland School of MedicineClass of 1993

Certifications & Licensure

FL State Medical License 1997 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer Start of enrollment: 2000 May 01
Terminated
Phase 2
Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2005 Mar 01
Completed
Phase 2
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment Start of enrollment: 2008 Dec 02
Completed
Not Applicable
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Jun 01
Unknown status
Phase 1, Phase 2
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer Start of enrollment: 2011 Nov 30
Completed
Phase 2
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma Start of enrollment: 2012 Jul 01
Completed
Phase 1
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer Start of enrollment: 2017 Apr 25
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer.
Jonathan Chatzkel, Michael J Schell, Jad Chahoud, Jingsong Zhang, Rohit Jain, Jennifer Swank, Steve Ludlow, Kristina Lombardi, Yesenia Lucas, Cortlin Croft, Jennifer R...> ;Clinical Genitourinary Cancer. 2022 Jun 1
4 citations
Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.
András Bibok, Rahul Mhaskar, Rohit Jain, Jingsong Zhang, Jessica M. Frakes, Sarah E. Hoffe, Ghassan El-Haddad, Nainesh Parikh, Altan Ahmed, Mayer Fishman, Junsung Choi...> ;Cardiovascular and Interventional Radiology. 2021 Jul 26
2 citations
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
Brian A. Costello, Nrupen A. Bhavsar, Yousef Zakharia, Sumanta K. Pal, Ulka N. Vaishampayan, Heather S.L. Jim, Mayer Fishman, Ana M. Molina, Christos Kyriakopoulos, Ch...> ;Clinical Genitourinary Cancer. 2021 Jul 10
37 citations
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Thomas E. Hutson, M. Dror Michaelson, Timothy M. Kuzel, Neeraj Agarwal, Ana M. Molina, James J. Hsieh, Ulka N. Vaishampayan, Ran Xie, Urmi Bapat, Weifei Ye, Rohit Jain...> ;European Urology. 2021 Apr 16
31 citations
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
Michael R. Harrison, Brian A. Costello, Nrupen A. Bhavsar, Ulka N. Vaishampayan, Sumanta K. Pal, Yousef Zakharia, Heather S.L. Jim, Mayer Fishman, Ana M. Molina, Chris...> ;Cancer. 2021 Jul 1
19 citations
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, Mayer Fishman, David F. McDermott, Daniel C. Cho, Ulka N. Vaishampayan, Saby George, Jamal Tarazi, William T. Du...> ;European Journal of Cancer. 2021 Mar 1
18 citations
Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings
Aasha I. Hoogland, Heather S.L. Jim, Brian D. Gonzalez, Brent J. Small, Danielle L. Gilvary, Elizabeth C. Breen, Julienne E. Bower, Mayer Fishman, Babu Zachariah, Paul...> ;Cancer. 2020 Dec 30
13 citations
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.
Jean-Francois Martini, Elizabeth R. Plimack, Toni K. Choueiri, David F. McDermott, Igor Puzanov, Mayer Fishman, Daniel C. Cho, Ulka N. Vaishampayan, Bradley Rosbrook, ...> ;Clinical Cancer Research. 2020 Nov 1
1 citations
Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").
Mayer Fishman> ;Translational Andrology and Urology. 2019 Sep 30
18 citations
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
Martin H. Voss, Rupal S. Bhatt, Nicholas J. Vogelzang, Mayer Fishman, Robert S. Alter, Brian I. Rini, J. Thaddeus Beck, Monika Joshi, Ralph J. Hauke, Michael B. Atkins...> ;Cancer. 2019 Jul 15
33 citations
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM re...
Mayer Fishman, Janice P. Dutcher, Joseph I. Clark, Ajjai Alva, Gerald P Miletello, Brendan Curti, Neeraj Agarwal, Ralph J. Hauke, Kathleen M. Mahoney, Helen Moon, J. T...> ;Journal for Immunotherapy of Cancer. 2019 Mar 27
91 citations
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna Pradyuman Patel, Shernan G. Holtan, Gerald P Miletello, Mayer Fishman, Rene Gon...> ;Journal for Immunotherapy of Cancer. 2019 Feb 18
89 citations
Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
Charles C. Peyton, Dominic H. Tang, Richard R. Reich, Mounsif Azizi, Juan Chipollini, Julio M. Pow-Sang, Brandon J. Manley, Philippe E. Spiess, Michael A. Poch, Wade J...> ;JAMA Oncology. 2018 Nov 1
14 citations
Comparing the relative importance of attributes of metastatic renal cell carcinoma treatments to patients and physicians in the United States: A discrete-choice experi...
Juan Marcos Gonzalez, Justin Doan, David Gebben, Marco Boeri, Mayer Fishman> ;Pharmacoeconomics. 2018 Aug 1
26 citations
Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
Michael A. Poch, MacLean Hall, Autumn Joerger, Krithika Kodumudi, Matthew Beatty, Pasquale P. Innamarato, Brittany L. Bunch, Mayer Fishman, Jingsong Zhang, Wade J. Sex...> ;Oncoimmunology. 2018 Jul 23
12 citations
Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience.
Charles C. Peyton, Mounsif Azizi, Juan Chipollini, Cesar Ercole, Mayer Fishman, Scott M. Gilbert, Timothy Juwono, Jorge L. Lockhart, Michael A. Poch, Julio M. Pow-Sang...> ;Clinical Genitourinary Cancer. 2018 May 18
259 citations
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, Mayer Fishman, David F. McDermott, Daniel C. Cho, Ulka N. Vaishampayan, Saby George, Thomas Olencki, Jamal Taraz...> ;The Lancet. Oncology. 2018 Mar 1
34 citations
Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia
Brian D. Gonzalez, Brent J. Small, Mallory G. Cases, Noelle L. Williams, Mayer Fishman, Paul B. Jacobsen, Heather S.L. Jim> ;Cancer. 2018 Feb 1
22 citations
Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison.
Kristine A. Donovan, Brian D. Gonzalez, Ashley M. Nelson, Mayer Fishman, Babu Zachariah, Paul B. Jacobsen> ;Psycho-Oncology. 2018 Jan 1
2 citations
Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive.
Mayer Fishman> ;Translational Andrology and Urology. 2017 Oct 1
653 citations
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
Thomas Powles, Peter H. O'Donnell, Christophe Massard, Hendrik Tobias Arkenau, Terence W. Friedlander, Christopher J. Hoimes, Jae-Lyun Lee, Michael Ong, Srikala S. Sri...> ;JAMA Oncology. 2017 Sep 14
33 citations
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer
Tanya B. Dorff, Jeff Longmate, Sumanta K. Pal, Walter M. Stadler, Mayer Fishman, Ulka N. Vaishampayan, Amol Rao, Jacek K. Pinksi, James S. Hu, David I. Quinn, Primo N....> ;Cancer. 2017 Aug 22
426 citations
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam B. Bhayani, William P Bro, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Mayer Fishman, Thoma...> ;Journal of the National Comprehensive Cancer Network. 2017 Jun 1
5 citations
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
Brian I. Rini, Victor Gruenwald, Eric Jonasch, Mayer Fishman, Yoshihiko Tomita, M. Dror Michaelson, Jamal Tarazi, Laura Cisar, Subramanian Hariharan, Angel H. Bair, Br...> ;Targeted Oncology. 2017 Jun 1
25 citations
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinom...
Joseph I. Clark, Michael K.K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, Lionel D. Lewis, John H. Stewart, ...> ;Clinical Genitourinary Cancer. 2017 Feb 1
Join now to see all

Lectures

Overall survivalÂ (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Tampa General Hospital Improves Access to Cancer Care and Treatment in the Riverview AreaSeptember 17th, 2021
Combination Axitinib + Pembrolizumab Active Against Renal Cell CarcinomaFebruary 16th, 2018
Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an on-Going Observational IL-2 Clinical Trial: PROCLAIM SMFebruary 1st, 2017
Join now to see all